CHINA MEDICAL SYSTEM HOLDINGS LIMITED
康哲藥業控股有限公司*

(Incorporated in the Cayman Islands with Limited Liability)

(Hong Kong Stock Code: 867)

(Singapore Stock Code: 8A8)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the “Board”) of China Medical System Holdings Limited (the “Company”) hereby announces that Mr. Lee Sien Liang, Joseph (“Mr. Lee”) was appointed as an independent non-executive director of the Company with effect from 29 June 2026.

Mr. Lee, aged 47, is currently the joint managing director and partner of LVM Law Chambers LLC, a Singapore-based international renowned law firm. Mr. Lee is a Singapore-qualified lawyer with over 22 years of legal practice experience in dispute resolution, commercial litigation and international arbitration. During his practice, he advised and represented clients in a broad range of complex commercial disputes, civil litigation matters and international arbitration proceedings.

Prior to co-founding LVM Law Chambers LLC, Mr. Lee was a partner at Dentons Rodyk & Davidson LLP, an international law firm, and worked at Jones Day and Baker McKenzie Wong & Leow in Singapore. He is a director at LVMT Private Ltd. and Kamiwayoi Pte. Ltd. He currently also serves as the founding company secretary of GDInstitute, an independent, non-profit organisation established to raise the standards of directorship and corporate governance in Singapore and the region. Mr. Lee has served and continues to serve on various professional disciplinary panels and committees, including the Law Society of Singapore, the Disciplinary Panel of the Singapore Dental Council and the Disciplinary Panel of the Council for Estate Agencies.

* *For identification purpose only*

Mr. Lee obtained his Bachelor of Laws degree from the National University of Singapore in 2003 and was admitted as an Advocate and Solicitor of the Supreme Court of Singapore in 2004.

On 29 June 2026, Mr. Lee entered into an appointment letter with the Company in his capacity as an independent non-executive director for a term of one year and is subject to retirement by rotation and re-election at the annual general meetings of the Company pursuant to its articles of association. Mr. Lee is entitled to receive director's emoluments of HK$360,000 per year, which was determined by the Remuneration Committee and the Board with reference to his qualifications, duties and responsibilities with the Company, the overall remuneration structure of the Company and the prevailing market conditions. Mr. Lee's remuneration shall be reviewed by the Remuneration Committee and the Board from time to time.

The Company is required to appoint one independent director whose country of principal residence is Singapore within one year of its listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Mr. Lee, who is currently resident in Singapore, has been appointed as an independent non-executive director of the Company for this purpose, and he satisfies the independence requirements under Rule 210(5)(d) of the Listing Manual of SGX-ST.

Save as disclosed herein, Mr. Lee has confirmed (i) he does not, and did not in the last three years, hold any directorship in listed public companies in Hong Kong or overseas or other major appointments and professional qualifications, nor does he hold any other position with the Company and its subsidiaries; (ii) he does not have any other relationship with any Directors, senior management, or substantial or controlling shareholders of the Company (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")); (iii) as at the date of this announcement, he does not hold any interest or short position in the securities of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); and (iv) he meets the independence criteria as set out in Rule 3.13 of the Listing Rules.

Mr. Lee has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that might affect his independence at the time of his appointment.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to the Rule 13.51(2) of the Rules Governing the Listing Securities on the

Stock Exchange, and there is no other matter that needs to be brought to the attention of the shareholders in relation to the appointment of Mr. Lee.

The Company would like to extend its sincere welcome to Mr. Lee on his appointment.

By Order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 29 June 2026

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong and Ms. Chen Yanling as executive directors; (ii) Mr. Leung Chong Shun, Ms. Luo Laura Ying, Mr. Fung Ching Simon and Mr. Lee Sien Liang, Joseph as independent non-executive directors.